Mark Barrett, who has held business development roles at Johnson & Johnson and Sanofi Genzyme, has taken an entrepreneur-in-residence position at Frazier Healthcare Partners.
Mark Barrett, formerly global head of strategy and business development at pharmaceutical firm Sanofi Genzyme, has joined the life sciences team of investment firm Frazier Healthcare Partners as entrepreneur-in-residence.
Barrett was responsible for Sanofi’s global rare diseases, immunology, multiple sclerosis and oncology businesses. He led the transaction team on Sanofi Genzyme’s $700m acquisition of a 12% stake in biopharmaceutical company Alnylam Pharmaceuticals in 2014.
Barrett also played a key role in Sanofi Genzyme’s $65m investment in gene therapy developer Voyager…
